EFFICIENCY OF INTEGRAL THERAPY AND POTENTIAL SIDE EFFECTS WHEN TREATING RESPIRATORY TUBERCULOSIS WITH MULTIPLE DRUG RESISTANCE
Abstract
Treatment of multiple drug resistant tuberculosis presents a serious challenge. Use of perchlozon (thioureidoiminomethylpyridini um) in the combination with the other five anti-tuberculosis drugs during 6 months of treatment allowed achieving cessation of bacillary excretion and X-ray improvement in all patients from the main group. Monitoring and evaluation of adverse events have not detected any confident difference in the number of adverse events apart from endocrine and allergic ones while taking perchlozon in the combination with other drugs. All adverse events were minor and moderate as regards severity degree and were managed by symptomatic treatment and did not cause cancellation of the drug. The obtained results will promote achieving the high tuberculosis treatment effciency by the end of the main chemotherapy course and this will require further investigation.
About the Authors
M. V. Pavlova
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
A. A. Starshinova
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
N. V. Sapozhnikova
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
I. V. Chernokhaeva
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
L. I. Archakova
St. Petersburg Research Institute of Phthisiopulmonology;
St. Petersburg State University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
P. K. Yablonskiy
St. Petersburg Research Institute of Phthisiopulmonology;
St. Petersburg State University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Balasanyants G.S., Sukhanov D.S., Аyzikov D.L. Pobochnye deystviya protivotuberkuleznykh preparatov i metody ikh ustraneniya: ucheb. posobie. [Side effects of anti-tuberculosis drugs and their management techniques. Manual]. St. Petersburg, 2011, 88 p.
2. Biostatistika: planirovanie, obrabotka i predstavlenie rezul’tatov biomeditsinskikh issledovaniy pri pomoschi sistemy SAS. [Biostatistics: planning, processing and presentation of results of biomedical studies with the help of SAS system]. St. Petersburg, Izd. Dom SPb MAPO Publ., 2005, 559 p.
3. Vinogradova T.I. et al. Efficiency evaluation of chemotherapy regimens for treatment of drug resistant experimental tuberculosis. Psikhofarmakol., Biol., Narkol., 2007, vol. 7, sp. iss., (p. 1) pp. 168. (In Russ.)
4. Vinogradova T.I. et al. Development of optimal treatment regimens of drug resistant tuberculosis in the experiment. Permsky Med. Journal, 2011, no. 1, pp. 88-93. (In Russ.)
5. Galkin V.B. et al. State of TB care provision for the population of Northern- Western Federal District in 2007-2012. Med. Alyans, 2013, no. 3. pp. 5-24. (In Russ.)
6. Ivanova L.А., Pavlova M.V., Аrchakova L.I. Treatment tactics for drug resistant pulmonary tuberculosis patients. Probl. Tub., 2003, no. 5, pp. 14-16. (In Russ.)
7. Klinicheskie rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya u vzroslykh. [Clinical recommendations for diagnostics and treatment of respiratory tuberculosis in adults]. (Epub.) Ed. by P.K. Yablonsky, Natsionalnaya Assotsiatsiya Ftiziatrov Publ., 2013, 48 p. – www.naph.ru.
8. Kononets A.S. Efficiency of individual chemotherapy regimens in pulmonary tuberculosis patients excreting multiple drug resistant tuberculous mycobacteria. Meditsina Krit. Sostoyaniy, 2008, no. 5/6, pp. 22-25. (In Russ.)
9. Nezhelatel’nye reaktsii: metod. rekomendatsii dlya vrachey. [Adverse events: doctors’ guidelines]. Ed. by A.M. Karpov, Kazan, 2005, 38 p.
10. Nechaeva O.B., Eysmont N.V. Impact of HIV-infection on tuberculosis epidemic in the Russian Federation. Epidemiol. i Gigiena, 2012, no. 4. pp. 6-13. (In Russ.)
11. Nizova A.V. et al. Analysis of resistance of clinical strains of Mycobacterium tuberculosis to the first and second line drugs. Epidemiologiya i Infekts. B-ni, 2007, no. 4, pp. 7-11. (In Russ.)
12. Perelman M.I. et al. Treatment of drug resistant tuberculosis. Antibiotiki i Khimioterapiya, 2003, no. 8, pp. 28-36. (In Russ.)
13. Pobochnye deystviya antibakterial’nykh khimioterapevticheskikh sredstv. [Side effects of anti-bacterial chemotherapy medications]. Edited by V.B. Kuzin, Protivomikrobnye Stredstva Publ., N. Novgorod, 2008, 68 p.
14. Edict no. 109 by RF MoH as of 21.03.2003 On Improvement of TB Control Measures in the Russian Federation (Revision as per Edict no. 855 by RF MoH as of 29.10.2009.) (In Russ.)
15. Protivotuberkulezny preparat Perkhlozon® v kompleksnom lechenii tuberkuleza organov dykhaniya: metodicheskie rekomendatsii. [The anti-tuberculosis drug of Perchlozan® in the integral treatment of respiratory tuberculosis: guidelines]. St. Petersburg, Irkutsk, 2013, 32 p.
16. Samoylova A.G. Organizatsiya lecheniya tuberkuleza s mnozhestvennoy lekarstvennoy ustoychivost’yu mikobakteriy v usloviyakh ugrozy razvitiya epidemii v Аrkhangel’skoy oblasti. Diss. kand. med. nauk. [Organisation of treatment of multiple drug resistant tuberculosis given the threat of the epidemic evelopment.
17. Cand. Diss.]. St. Petersburg, 2008, 20 p.
18. Sokolova G.B. et al. Clinical, X-ray and bacteriological specifics of drug resistant tuberculosis. Probl. Tub., 2006, no. 12, pp. 16-20. (In Russ.)
19. Sterlikov S.A. Characteristics and outcomes of the main treatment course of new pulmonary tuberculosis patients, registered in 2011. Tub., 2014, no. 7, pp. 16-20. (In Russ.)
20. Sukhanov D.S., Pavlova M.V., Yablonskiy P.K. et al. Comparative efficiency of clinical use of reamberin, remaxol and ademetionine in respiratory tuberculosis patients with liver lesions. Antibiotiki i Khimioterapiya, 2013, vol. 58, no. 1-2, pp. 13-19. (In Russ.)
21. Tuberkulez v Rossiyskoy Federatsii, 2011 g. Analitichesky obzor. [Tuberculosis in the Russian Federation. 2011. Analytical review]. Moscow, 2013, 280 p.
22. Shilova M.V. Organization of TB care in Russia and ways of its modernization of organizational and methodical management of dispensary follow up of tuberculosis patients under current epidemic and socio-economic conditions. Tub., 2011, no. 5, pp. 236. (In Russ.)
23. Shilova M.V. The improvement of dispensary follow-up of contingents of TB control facilities on the basis of personified monitoring with the use of information technology (justification and implementation conditions). Tub., 2014, no. 7, pp. 8-15. (In Russ.)
24. Yablonsky P.K. et al. Guidelines on using the anti-tuberculosis drug of Perchlozon in the itegral treatment of respiratory tuberculosis. Med. Alyans, 2013, no. 2, pp. 69-81. (In Russ.)
25. Yablonsky P.K. Russian tuberculosis control - the choice of the way for further development. Med. Alyans, 2013, no. 3, pp. 5-24. (In Russ.)
26. Common Terminology Criteria for Adverse Events V3.0. Cancer Therapy Evaluation Program. December 12, 2003 (www.ctep.cancer.gov).
27. Dharmadhikari A.S. et al. Rapid impact of effective treatment on transmission of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis., 2014, vol. 18, no. 9, pp. 1019-1025.
28. Hwang T.J. et al. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int.J. Tuberc. Lung Dis., 2013, vol. 17, no. 10, pp. 1257-1266.
29. Khatri G.R., Frieden T.R. The status and prospects of tuberculosis control in India. Int. J. Tuberc. Lung Dis., 2000, vol. 4. pp. 193-200.
30. Lienhardt C. et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J. Infect. Dis., 2012, vol. 205, suppl. 2. pp. S241-S249.
31. World Health Organization Global tuberculosis report, 2012.
32. World Health Organization Global tuberculosis report, 2013.
Review
For citations:
Pavlova M.V., Starshinova A.A., Sapozhnikova N.V., Chernokhaeva I.V., Archakova L.I., Yablonskiy P.K. EFFICIENCY OF INTEGRAL THERAPY AND POTENTIAL SIDE EFFECTS WHEN TREATING RESPIRATORY TUBERCULOSIS WITH MULTIPLE DRUG RESISTANCE. Tuberculosis and Lung Diseases. 2015;(12):61-67. (In Russ.)
Views:
804
Email this article 